A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

This study is comparing two treatment paths for older adults (65+) with acute myeloid leukemia (AML) who have responded to initial chemotherapy with azacitidine and venetoclax: continuing with more cycles of the same chemotherapy versus proceeding to a stem cell transplant (bone marrow transplant). **You may be eligible if...** - You are 65 years old or older - You have confirmed acute myeloid leukemia (AML) - You are currently being treated with azacitidine and venetoclax - Your heart, liver, and kidney function are adequate to be considered for a stem cell transplant **You may NOT be eligible if...** - Your AML has not responded to the initial chemotherapy - You have severe organ dysfunction that rules out transplant eligibility - You are not willing to be randomly assigned between treatments - You have active uncontrolled infections Talk to your doctor to see if this trial is right for you.